VEGFA and colorectal cancer: However, due to the lack of relevant research data, the treatment of SRCC-A is mainly inferred based on the data of colorectal cancer, and adjuvant treatment based on 5-FU chemotherapy is preferred, and the majority of patients adopt FOLFOX regimen, or in combination with bevacizumab based on data demonstrated therapeutic efficacy for metastatic colon cancer.[7,14,28,29] Bevacizumab is an inhibitor of angiogenesis specific to vascular endothelial growth factor (VEGF).